• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by DiaMedica Therapeutics Inc.

    7/8/24 5:23:49 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMAC alert in real time by email
    SC 13G 1 d11408321_13-g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No)*

     

     

    DiaMedica Therapeutics Inc.
    (Name of Issuer)

     

     

    Voting common shares, no par value per share
    (Title of Class of Securities)

     

     

    25253X207
    (CUSIP Number)

     

     

    June 28, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No 25253X207    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Dialectic Life Sciences SPV LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,173,529  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,173,529  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,173,529  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.1%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     

     

     

    CUSIP No 25253X207    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Dialectic LS Manager LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,173,529  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,173,529  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,173,529  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.1%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     

     

     

    CUSIP No 25253X207    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Dialectic Capital Management, LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,173,529  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,173,529  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,173,529  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.1%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     
     

     

     

    CUSIP No 25253X207    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Dialectic Partners, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,173,529  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,173,529  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,173,529  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.1%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     
     

     

     

    CUSIP No 25253X207    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      John Fichthorn  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,205,795  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,205,795  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,205,795  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.2%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

     

     

     

     

     

    CUSIP No 25253X207    

     

    Item 1. (a). Name of Issuer:  
           
        DiaMedica Therapeutics Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    301 Carlson Parkway, Suite 210

    Minneapolis, Minnesota 55305

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Dialectic Life Sciences SPV LLC

    Dialectic LS Manager LLC

    Dialectic Capital Management, LP

    Dialectic Partners, LLC

    John Fichthorn

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Dialectic Life Sciences SPV LLC

    Dialectic LS Manager LLC

    119 Rowayton Avenue, 2nd Floor

    Norwalk, Connecticut 06853

     

    Dialectic Capital Management, LP

    Dialectic Partners, LLC

    119 Rowayton Avenue, 2nd Floor

    Norwalk, Connecticut 06853

     

    John Fichthorn

    c/o Dialectic Capital Management LP

    119 Rowayton Avenue, 2nd Floor

    Norwalk, Connecticut 06853

     

     

      (c).

    Citizenship:

     

    Dialectic Life Sciences SPV LLC – Delaware limited liability company

    Dialectic LS Manager LLC – Delaware limited liability company

    Dialectic Capital Management, LP – Delaware limited partnership

    Dialectic Partners, LLC – Delaware limited liability company

    John Fichthorn – United States citizen

      (d). Title of Class of Securities:  
           
        Voting common shares, no par value per share  

     

      (e). CUSIP Number:  
           
        25253X207  

     

     

     

    Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).

     

      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(©(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under Sec©n 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:

     

       

    2,173,529 shares deemed beneficially owned by Dialectic Life Sciences SPV LLC

    2,173,529 shares deemed beneficially owned by Dialectic LS Manager LLC

    2,173,529 shares deemed beneficially owned by Dialectic Capital Management, LP

    2,173,529 shares deemed beneficially owned by Dialectic Partners, LLC

    2,205,795 shares deemed beneficially owned by John Fichthorn

     

      (b) Percent of class:

     

       

    5.1% deemed beneficially owned by Dialectic Life Sciences SPV LLC

    5.1% deemed beneficially owned by Dialectic LS Manager LLC

    5.1% deemed beneficially owned by Dialectic Capital Management, LP

    5.1% deemed beneficially owned by Dialectic Partners, LLC

    5.2% deemed beneficially owned by John Fichthorn

     

        Number of shares as to which Dialectic Life Sciences SPV LLC has:

     

        (i) Sole power to vote or to direct the vote 0
             
        (ii)   Shared power to vote or to direct the vote 2,173,529
             
        (iii) Sole power to dispose or to direct the disposition of 0
             
        (iv)   Shared power to dispose or to direct the disposition of 2,173,529

     

     

     

        Number of shares as to which Dialectic LS Manager LLC has:

     

        (i) Sole power to vote or to direct the vote 0
             
        (ii)   Shared power to vote or to direct the vote 2,173,529
             
        (iii) Sole power to dispose or to direct the disposition of 0
             
        (iv)   Shared power to dispose or to direct the disposition of 2,173,529

     

        Number of shares as to which Dialectic Capital Management, LP has:

     

        (i) Sole power to vote or to direct the vote 0
             
        (ii)   Shared power to vote or to direct the vote 2,173,529
             
        (iii) Sole power to dispose or to direct the disposition of 0
             
        (iv)   Shared power to dispose or to direct the disposition of 2,173,529

     

        Number of shares as to which Dialectic Partners, LLC has:

     

        (i) Sole power to vote or to direct the vote 0
             
        (ii)   Shared power to vote or to direct the vote 2,173,529
             
        (iii) Sole power to dispose or to direct the disposition of 0
             
        (iv)   Shared power to dispose or to direct the disposition of 2,173,529

     

        Number of shares as to which John Fichthorn has:

     

        (i) Sole power to vote or to direct the vote 0
             
        (ii)   Shared power to vote or to direct the vote 2,205,795
             
        (iii) Sole power to dispose or to direct the disposition of 0
             
        (iv)   Shared power to dispose or to direct the disposition of 2,205,795

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
       
      N/A
       

     

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      All securities reported in this Schedule 13G are owned by advisory clients of Dialectic Capital Management, LP and/or its related persons' proprietary accounts.  Other than the reporting persons listed herein, none of such persons individually own more than 5% of DiaMedica Therapeutics Inc. outstanding shares.
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
       

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      July 8, 2024
      (Date)

     

    Dialectic Life Sciences SPV LLC

    By: Dialectic LS Manager LLC

    Its Manager

     

     

     

    /s/ John Fichthorn
    Signature


     

    Dialectic LS Manager LLC

     

      /s/ John Fichthorn
    Signature


         

    Dialectic Capital Management, LP

    By: Dialectic Partners, LLC

    Its General Partner

      /s/ John Fichthorn
    Signature


     

    Dialectic Partners, LLC

     

     

    /s/ John Fichthorn
    Signature

         
    John Fichthorn   /s/ John Fichthorn
    Signature
         

     

     

     

     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G dated July 8, 2024 relating to the Voting common shares, no par value per share of DiaMedica Therapeutics Inc. shall be filed on behalf of the undersigned.

     

     

    Dialectic Life Sciences SPV LLC

    By: Dialectic LS Manager LLC

    Its Manager

     

     

     

    /s/ John Fichthorn
    Signature


     

    Dialectic LS Manager LLC   /s/ John Fichthorn
    Signature


         

    Dialectic Capital Management, LP

    By: Dialectic Partners, LLC

    Its General Partner

      /s/ John Fichthorn
    Signature


     

    Dialectic Partners, LLC

     

     

    /s/ John Fichthorn
    Signature

         
    John Fichthorn   /s/ John Fichthorn
    Signature
         

     

     

     

     

    Get the next $DMAC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DMAC

    DatePrice TargetRatingAnalyst
    10/7/2024$7.00Buy
    H.C. Wainwright
    4/24/2024$8.00Buy
    Craig Hallum
    6/22/2023$7.00Perform → Outperform
    Oppenheimer
    6/30/2021$38.00 → $32.00Buy
    Roth Capital
    More analyst ratings

    $DMAC
    SEC Filings

    See more
    • DiaMedica Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      5/15/25 4:46:50 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by DiaMedica Therapeutics Inc.

      10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      5/13/25 4:31:55 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      5/13/25 4:30:49 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Business Officer Wambeke David J.

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      6/3/25 4:19:13 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Semba Charles Pauling

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      6/3/25 4:18:43 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President & CEO Pauls Dietrich John

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      6/3/25 4:18:01 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

      H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00

      10/7/24 7:50:42 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum resumed coverage on DiaMedica Therapeutics with a new price target

      Craig Hallum resumed coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $8.00

      4/24/24 8:38:29 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded DiaMedica Therapeutics from Perform to Outperform and set a new price target of $7.00

      6/22/23 7:34:26 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investable U.S. equity market. The Russell 2000 Index is a subset of the Russell 3000, measuring the performance of the small-cap segment. These indexes are widely used by investment managers and institutional investors for index funds

      6/24/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in New York City, NY, June 3 – 5, 2025. Management will be available for one-on-one meetings with investors to discuss the company's strategy, recent developments and future outlook in greater detail. Presentation Details: Date & Time: June 4, 2025, 12:50 PM Eastern Time Location: New York City, NY About DM199 (rinvecalinase alfa) DM199 (rinvecalin

      5/22/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

      Company to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM Central DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the clinical trial design and endpoints of the DM199 Phase 2 preeclampsia study. The webinar will feature Prof. Stephen Tong, MD, PhD (The University of Melbourne), Prof. Susan Walker, MD, PhD (The University of Melbourne), and Prof. Baha Sibai, MD (Un

      5/19/25 9:00:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Von Koch Thomas bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:27:16 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Stahlberg Jan bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:24:38 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wambeke David J. bought $49,200 worth of Voting Common Shares (20,000 units at $2.46), increasing direct ownership by 4% to 527,114 units (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      11/16/23 4:37:28 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Financials

    Live finance-specific insights

    See more
    • DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

      Conference Call and Webcast May 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Topline DM199 Preeclampsia Phase 2 Part 1A Proof of Concept Results Expected in Near Term and Phase 2 Part 1B Expected to Initiate in Q3 2025 KOL Event Scheduled for May 28, 2025 to Discuss the Disease of Preeclampsia and the Ongoing DM199 Phase 2 Study Design Acute Ischemic Stroke Phase 2/3 Program Enrollment Progressing as Planned Cash Runway into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the quarter ended M

      5/13/25 4:30:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

      5/7/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

      Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time  Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing Appointed Experienced Biotech Executive Daniel J. O'Connor to the Board Cash Runway into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, M

      3/17/25 4:30:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Leadership Updates

    Live Leadership Updates

    See more
    • DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher

      2/24/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

      Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

      1/22/24 8:23:00 AM ET
      $DMAC
      $MRNS
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

      Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica's manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug applic

      9/12/23 8:13:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by DiaMedica Therapeutics Inc.

      SC 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)

      7/8/24 5:23:49 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

      SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

      6/27/23 4:12:06 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

      SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

      6/27/23 4:11:32 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care